Investigation of prolactin-related vasoinhibin in sera from patients with diabetic retinopathy

European Journal of Endocrinology

Volumn 161, Issue 2, 2009, Pages 345-353

  Triebel, Jakob ^a   Huefner, Michael ^b   Ramadori, Giuliano ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Endokrinologikum Göttingen ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBIN; PROLACTIN RELATED VASOINHIBIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; PROLACTIN; VASH1 PROTEIN, HUMAN;

ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; QUANTITATIVE STUDY; SENSITIVITY ANALYSIS; AGED; BLOOD; CHEMOLUMINESCENCE; EPITOPE MAPPING; IMMUNOPRECIPITATION; METHODOLOGY; MICROFLUIDICS; MIDDLE AGED;

AGED; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CHEMILUMINESCENT MEASUREMENTS; DIABETES MELLITUS; DIABETIC RETINOPATHY; EPITOPE MAPPING; HUMANS; IMMUNOPRECIPITATION; MALE; MICROFLUIDICS; MIDDLE AGED; PROLACTIN;

EID: 68349154946     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0130     Document Type: Article

References (25)

1. Klein R, Klein BEK, Moss SE, Davis MD & DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. Journal of the American Medical Association 1988 260 2864-2871. (Pubitemid 18266031)
2. Frank RN. Diabetic retinopathy. New England Journal of Medicine 2004 350 48-58.
3. Clapp C, López-Gómez FJ, Nava G, Corbacho A, Torner L, Macetola Y, Duenas Z, Ochoa A, Noris G, Acosta E, Garay E & Martínez de la Escalera G. Expression of prolactin mRNA and of prolactin-like proteins in endothelial cells: evidence for autocrine effects. Journal of Endocrinology 1998 158 137-144. (Pubitemid 28322519)
4. Ben-Jonathan N, Mershon JL, Allen DL & Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocrine Reviews 1996 17 639-669. (Pubitemid 26425260)
5. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocrine Reviews 1995 16 354-369.
6. Piwnica D, Touraine P, Struman I, Tabruyn S, Bolbach G, Clapp C, Martial JA, Kelly PA & Goffin V. Cathepsin D processes human prolactin into multiple 16 K-like N-terminal fragments: study of their antiangiogenetic properties and physiological relevance. Molecular Endocrinolgy 2004 18 2522-2542. (Pubitemid 39335986)
7. Khurana S, Liby K, Buckley AR & Ben-Jonathan N. Proteolysis of human prolactin: resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin. Endocrinology 1999 140 4127-4132.
8. Clapp C, Martial JA, Guzman RC, Rentier-Delrue F & Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993 133 1292-1299. (Pubitemid 23267784)
9. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI & Martial JA. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. PNAS 1999 96 1246-1251. (Pubitemid 29098436)
10. Clapp C, Aranda J, Gonzalez C, Jeziorski MC & Martínez de la Escalera G. Vasoinhibins: endogenous regulators of angiogenesis and vascular function. Trends in Endocrinology and Metabolism 2006 17 301-307. (Pubitemid 44397566)
11. Corbacho AM, Martínez de la Escalera G & Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. Journal of Endocrinology 2002 173 219-238. (Pubitemid 34552451)
12. Aranda J, Rivera JC, Jeziorsky MC, Riesgo-Escovar J, Nava G, López-Barrera F, Quiróz-Mercado H, Berger P, Martínez de la Escalera G & Clapp C. Prolactins are natural inhibitors of angiogenesis in the retina. Investigative Ophthalmology and Visual Science 2005 46 2947-2953. (Pubitemid 43086718)
13. Garcia C, Aranda J, Arnold E, Thébault S, Macetola Y, López-Casillas F, Mendoza V, Quiróz-Mercado H, Hernández-Montiel LH, Lin SH, Martínez de la Escalera G & Clapp C. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. Journal of Clinical Investigation 2008 118 2291-2300. (Pubitemid 351872346)
14. Clapp C, Thebault S, Arnold E, Garcia C, Rivera JC & Martínez de la Escalera G. Vasoinhibins: novel inhibitors of ocular angiogenesis. American Journal of Physiology. Endocrinology and Metabolism 2008 295 E772-E778.
15. Early Treatment Diabetic Retinopathy Study Research Group. Results from the early treatment diabetic retinopathy study. Ophthalmology 1991 98 739-840.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995 1 27-31.
17. Folkman J & Klagsburn M. Angiogenic factors. Science 1987 325 442-447.
18. Nyberg P, Xie L & Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Research 2005 65 3967-3979.
19. Maier R, Weger M, Haller-Schober EM, El-Shabrawi Y, Wedrich A, Theisl A, Aigner R, Barth A & Haas A. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Molecular Vision 2008 14 637-643.
20. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AEB, Al-Shabrawey M, Platt DH & Caldwell RW. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes/Metabolism Research and Reviews 2003 19 442-455. (Pubitemid 37536961)
21. Leanos-Miranda A, Marquez-Acosta J, Cardenas-Mondragon GM, Chinolla-Arellano ZL, Rivera-Leanos R & Bermejo-Huerta S. Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes. Journal of Clinical Endocrinology and Metabolism 2008 93 2492-2499. (Pubitemid 352008512)
22. Ben-Jonathan N, LaPensee CR & LaPensee EW. What can we learn from rodents about prolactin in humans? Endocrine Reviews 2008 29 1-41.
23. O'Steen WK & Sundberg DK. Patterns of radioactivity in the eyes of rats after injections of iodinated prolactin. Ophthalmic Research 1982 14 54-62.
24. Ochoa A, Montes de Oca P, Rivera JC, Duenas Z, Nava G, Martínez de la Escalera G & Clapp C. Expression of prolactin gene and secretion of prolactin by rat retinal capillary endothelial cells. Investigative Ophthalmology and Visual Science 2001 42 1639-1645. (Pubitemid 32520759)
25. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQN, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A & Drexler H. A cathepsin D-cleaved 16 kDa form of prolactin mediates post partum cardiomyopathy. Cell 2007 128 589-600. (Pubitemid 46206082)